Lipocine announces phase 2 data on lpcn 2401 to be presented at obesityweek®

Study evaluated lpcn 2401 in participants with obesity (bmi ≥30) and participants with bmi ≥27 with at least one weight-related comorbidity salt lake city , sept. 5, 2024 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that a poster featuring phase 2 data on lpcn 2401 will be presented at the obesity society's annual obesityweek® conference to be held november 3 – 6, 2024 in san antonio, tx.
LPCN Ratings Summary
LPCN Quant Ranking